載入中
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
收盤時
US$7.26
−US$0.51 · -6.56%
盤後
US$7.3465
+US$0.0865 · +1.19%
10月13日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
日內區間
目前US$7.26
52週區間
目前US$7.26
盤中時間採用ET。市場資料可能有所延遲。
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
日內區間
目前US$7.26
52週區間
目前US$7.26
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.7億 USD | 8332.8萬 USD | 9024.2萬 USD | 1.13億 USD | 4.7億 USD |
| 銷貨成本 | 2029.8萬 USD | 3356.7萬 USD | 3721.3萬 USD | 5454.5萬 USD | 5183.3萬 USD |
| 毛利 | 1.5億 USD | 4976.1萬 USD | 5302.9萬 USD | 5817.9萬 USD | 4.19億 USD |
| 研究與開發 | 2.28億 USD | 2.09億 USD | 2.32億 USD | 2.42億 USD | 1.81億 USD |
| 銷售、一般及管理費用 | 8286.3萬 USD | 7661.9萬 USD | 8849.4萬 USD | 8528.1萬 USD | 7933.3萬 USD |
| 營業費用 | 3.11億 USD | 2.83億 USD | 3.21億 USD | 3.21億 USD | 2.59億 USD |
| 利息收入 | 1226.6萬 USD | 17.4萬 USD | 2.5萬 USD | 34.2萬 USD | 71.9萬 USD |
| 利息支出 | 4500.8萬 USD | 1265.9萬 USD | 686.2萬 USD | 2325.4萬 USD | 2627.7萬 USD |
| 折舊和攤銷 | 1561.5萬 USD | 1621.5萬 USD | 1732萬 USD | 1290.9萬 USD | 956.4萬 USD |
| 營業利益 | −1.61億 USD | −2.33億 USD | −2.68億 USD | −2.63億 USD | 1.6億 USD |
| 淨利 | −1.94億 USD | −2.27億 USD | −2.63億 USD | −2.8億 USD | 1.28億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$20.00
上漲空間 175.48%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1676.98萬0.00%2.3兆 USD0.03%US$381.32-0.07%
State Street SPDR S&P Biotech ETFXBI1605.47萬0.16%103.03億 USD0.35%US$146.8-3.04%
iShares Russell 2000 ETFIWM1174.57萬0.02%777.48億 USD0.19%US$276.7-0.43%
Vanguard Extended Market ETFVXF534.81萬0.01%954億 USD0.05%US$232.54-0.42%
iShares Biotechnology ETFIBB369.51萬0.03%107.38億 USD0.44%US$200.02-2.08%
Fidelity Enhanced Small Cap ETFFESM369.48萬0.06%64.1億 USD0.28%US$45.15-0.20%
iShares Russell 2000 Growth ETFIWO353.87萬0.03%137.9億 USD0.24%US$351.1-0.74%
Vanguard Russell 2000 ETFVTWO263.25萬0.01%180億 USD0.06%US$111.77-0.45%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
